Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging

Molecular Medicine Reports

Volumn 4, Issue 6, 2011, Pages 1289-1293

  Bu, Liang ^a   Jiang, Guanchao ^a   Yang, Fan ^a   Liu, Jun ^a   Wang, Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Laser capture microdissection; Non small cell lung cancer; Polyclonal antibody; Solute carrier family 35 member F2; Tissue microarray

Indexed keywords

POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY SLC35F2; PROTEIN ANTIBODY; RNA; SOLUTE CARRIER FAMILY 35 MEMBER F2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE MICROARRAY; TUMOR GENE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

HOMO SAPIENS;

EID: 80053097632     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.572     Document Type: Article

References (16)

1. Stankovic T, Byrd PJ and Cooper PR: Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genes. Genomics 40: 267-276, 1997. (Pubitemid 27124089)
2. Nishimura M, Suzuki S and Satoh T: Tissue-specific mRNA expression profiles of human solute carrier 35 transporters. Drug Metab Pharmacokinet 24: 91-99, 2009.
3. Bangsow T, Baumann E and Bangsow C: The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J Cereb Blood Flow Metab 28: 1249-1260, 2008. (Pubitemid 351733349)
4. Shen C, Zhao H and Wang D: Molecular cloning, identification and analysis of lung squamous cell carcinoma-related genes. Lung Cancer 38: 235-241, 2002. (Pubitemid 35345177)
5. Zang LQ, Qiu PX and Xiao R: [Bioinformatics analysis of YZ-2 protein and polyclonal antibody preparation]. Chinese J Cell Mol Immunol 22: 205-207, 2006 (In Chinese).
6. Liu HY, Yang W and Wu ZH: [Cytochrome P450 3A4 epitope analysis and antibody preparation and identification]. Chinese J Cell Mol Immunol 23: 79-81, 2007 (In Chinese).
7. Li T, Guo H and Wang Y: [Anti-CMTM4 polyclonal antibody preparation, purification and identification]. Chinese J Cell Mol Immunol 24: 41-44, 2008 (In Chinese).
8. Shi S, Zhang YM and Qiu XY: Anti-chemokine-like factor-1 polypeptide antibody preparation, identification and tissue microarray analysis. Acta Academiae Medicinae Sinicae 26: 496-509, 2004.
9. Sugiyama Y, Sugiyama K and Hirai Y: Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 117: 109-116, 2002. (Pubitemid 34052480)
10. Jacquet R and Hillyer J: Analysis of connective tissues by laser capture microdissection and reverse transcriptase-polymerase chain reaction. Anal Biochem 337: 22-34, 2005. (Pubitemid 40092775)
11. Hao Q, Xu Y and Li WL: The combined application of laser capture microdissection and linear RNA amplification methods in the study of bladder transitional cell carcinoma related genes. Chinese J Exper Surg 22: 864-867, 2005.
12. Feng JZ, Qin LX and Ren N: Loss of heterozygous study of short arm on chromosome 8 in hepatocellular carcinoma cells by laser capture microdissection. Chinese J Exper Surg 23: 284-287, 2006.
13. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909, 1995.
14. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
15. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB and Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001. (Pubitemid 32591438)
16. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (Suppl 4): 2-8, 2002.